Pfizer and Moderna vaccines prove 92 percent effective with just 1st dose


Just one dose of the Moderna and Pfizer two-shot coronavirus vaccines is seemingly nearly as good two.
In a study published Thursday in the New England Journal of Medicine, a pair of Canadian-based researchers suggested an amendment to the determined efficacy of the Pfizer vaccines after just one shot. While Pfizer and BioNTech reported their vaccine was just 52.4 percent effective at preventing infection after the first dose, the researchers noted that this data includes results from within the first two weeks after inoculation, "when immunity would have still been mounting." After two weeks, that efficacy mounted to 92.6 percent, matching the first-dose efficacy of 92.1 percent reported from the Moderna vaccine as well. After two doses, the Pfizer vaccine is 95 percent effective, and Moderna's is 94 percent.
The Canadian-based researchers' interpretations of the Pfizer results led them to suggest in the letter that vaccine distributors delay giving people the second dose. This would let distributors get first doses to more at-risk people instead of leaving them "completely unprotected" — something the researchers called "a matter of national security that, if ignored, will certainly result in thousands of COVID-19–related hospitalizations and deaths this winter in the United States."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Another study from January led Pfizer and BioNTech to say Wednesday that they are unsure if the vaccine will be effective at protecting against the B.1.351 variant first found in South Africa. The study published in the New England Journal of Medicine found the vaccine was still capable of neutralizing the virus within the B.1.351 strain, and that trials haven't shown the variant reduces the vaccine's protection in people. Still, the companies may end up creating a booster shot to ensure the vaccine remains effective against the highly transmissible strain.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
Social Security: Insolvency date keeps getting closer
Feature A new report has projected that Social Security funds could be depleted by 2033
-
Are AI lovers replacing humans?
Talking Points A third of Gen Z singles use tech as a 'romantic companion'
-
What are the Trump Accounts for kids and how do they work?
The Explainer Parents will soon be able to open tax-advantaged investment accounts on their child's behalf
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths